18F-FPPRGD2 PET/CT: Pilot phase evaluation of breast cancer patients

Radiology

Volumn 273, Issue 2, 2014, Pages 549-559

  Iagaru, Andrei ^a   Mosci, Camila ^a   Shen, Bin ^a   Chin, Frederick T ^a   Mittra, Erik ^a   Telli, Melinda L ^a   Gambhir, Sanjiv Sam ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 FLUOROPROPIONYL LABELED PEGYLATED DIMERIC ARGININE GLYCINE ASPARTIC ACID PEPTIDE F 18; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; ARGINYL-GLYCYL-ASPARTIC ACID; FLUORINE; OLIGOPEPTIDE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER PATIENT; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL PROTOCOL; COMPUTER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG SAFETY; DRUG TOLERABILITY; DRUG UPTAKE; ELECTROCARDIOGRAM; FEMALE; HUMAN; METASTASIS; MULTIVARIATE ANALYSIS OF VARIANCE; NONPARAMETRIC TEST; OUTCOME ASSESSMENT; PET-CT SCANNER; PILOT STUDY; PROSPECTIVE STUDY; STUDENT T TEST; VITAL SIGN; BREAST TUMOR; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON EMISSION TOMOGRAPHY; RADIOGRAPHY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY;

ADULT; BREAST NEOPLASMS; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; MIDDLE AGED; MULTIMODAL IMAGING; OLIGOPEPTIDES; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84910047513     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.14140028     Document Type: Article

References (36)

1. Leite de Oliveira R, Hamm A, Mazzone M. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies. Mol Aspects Med 2011;32(2):71-87.
2. Higgins MJ, Baselga J. Targeted therapies for breast cancer. J Clin Invest 2011;121(10): 3797-3803.
3. Eliceiri BP, Cheresh DA. Role of alpha v integrins during angiogenesis. Cancer J 2000;6(Suppl 3):S245-S249.
4. Felding-Habermann B, O'Toole TE, Smith JW, et al. Integrin activation controls metastasis in human breast cancer. Proc Natl Acad Sci U S A 2001;98(4):1853-1858.
5. Kerr JS, Slee AM, Mousa SA. The alpha v integrin antagonists as novel anticancer agents: An update. Expert Opin Investig Drugs 2002;11(12):1765-1774.
6. Gilbert MR, Kuhn J, Lamborn KR, et al. Cilengitide in patients with recurrent glioblastoma: The results of NABTC 03-02, a phase II trial with measures of treatment delivery. J Neurooncol 2012;106(1):147-153.
7. Vermorken JB, Guigay J, Mesia R, et al. Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part. Br J Cancer 2011;104(11):1691-1696.
8. Stupp R, Hegi ME, Neyns B, et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 2010;28(16):2712-2718.
9. Alva A, Slovin S, Daignault S, et al. Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium. Invest New Drugs 2012;30(2):749-757.
10. Haubner R, Wester HJ. Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies. Curr Pharm Des 2004;10(13):1439-1455.
11. Giovannini M, Aldrighetti D, Zucchinelli P, Belli C, Villa E. Antiangiogenic strategies in breast cancer management. Crit Rev Oncol Hematol 2010;76(1):13-35.
12. Derleth C, Mayer IA. Antiangiogenic therapies in early-stage breast cancer. Clin Breast Cancer 2010;10(Suppl 1):E23-E31.
13. Lopes G, Dent R. Weighed, measured, and still searching: bevacizumab in the treatment of unselected patients with advanced breast cancer. Oncologist 2011;16(12):1669-1671.
14. Pivot X, Schneeweiss A, Verma S, et al. Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results from AVADO. Eur J Cancer 2011;47(16): 2387-2395.
15. Robert NJ, Diéras V, Glaspy J, et al. RIBBON- 1: randomized, double-blind, placebocontrolled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011;29(10):1252-1260.
16. Mittra ES, Goris ML, Iagaru AH, et al. Pilot pharmacokinetic and dosimetric studies of (18)F-FPPRGD2: A PET radiopharmaceutical agent for imaging a(v)b(3) integrin levels. Radiology 2011;260(1):182-191.
17. Chin FT, Shen B, Liu S, et al. First experience with clinical-grade ([18F]FPP(RGD2): An automated multi-step radiosynthesis for clinical PET studies. Mol Imaging Biol 2012;14(1):88-95.
18. Delbeke D, Coleman RE, Guiberteau MJ, et al. Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med 2006;47(5):885-895.
19. Nordhausen K, Oja H. Multivariate L1 Statistical Methods: The Package MNM. J Stat Softw 2011;43(5):1-28.
20. Newcombe RG. Improved confidence intervals for the difference between binomial proportions based on paired data. Stat Med 1998;17(22):2635-2650.
21. Graham MM, Badawi RD, Wahl RL. Variations in PET/CT methodology for oncologic imaging at U.S. academic medical centers: An imaging response assessment team survey. J Nucl Med 2011;52(2): 311-317.
22. Cai W, Chen X. Multimodality molecular imaging of tumor angiogenesis. J Nucl Med 2008;49(Suppl 2):113S-128S.
23. Chen X. Multimodality imaging of tumor integrin alphavbeta3 expression. Mini Rev Med Chem 2006;6(2):227-234.
24. Haubner R, Weber WA, Beer AJ, et al. Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F] Galacto-RGD. PLoS Med 2005;2(3):e70.
25. Beer AJ, Haubner R, Sarbia M, et al. Positron emission tomography using [18F] Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. Clin Cancer Res 2006;12(13):3942-3949.
26. Beer AJ, Niemeyer M, Carlsen J, et al. Patterns of alphavbeta3 expression in primary and metastatic human breast cancer as shown by 18F-Galacto-RGD PET. J Nucl Med 2008;49(2):255-259.
27. Beer AJ, Grosu AL, Carlsen J, et al. [18F] galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 2007;13(22 Pt 1): 6610-6616.
28. Beer AJ, Lorenzen S, Metz S, et al. Comparison of integrin alphaVbeta3 expression and glucose metabolism in primary and metastatic lesions in cancer patients: A PET study using 18F-galacto-RGD and 18F-FDG. J Nucl Med 2008;49(1):22-29.
29. Liu S, Liu Z, Chen K, et al. 18F-labeled galacto and PEGylated RGD dimers for PET imaging of avb3 integrin expression. Mol Imaging Biol 2010;12(5):530-538.
30. McParland BJ, Miller MP, Spinks TJ, et al. The biodistribution and radiation dosimetry of the Arg-Gly-Asp peptide 18FAH111585 in healthy volunteers. J Nucl Med 2008;49(10):1664-1667.
31. Kenny LM, Coombes RC, Oulie I, et al. Phase I trial of the positron-emitting Arg- Gly-Asp (RGD) peptide radioligand 18FAH111585 in breast cancer patients. J Nucl Med 2008;49(6):879-886.
32. 18F]fluciclatide in metastatic breast cancer patients. Eur J Nucl Med Mol Imaging 2011;38(12): 2186-2197.
33. Doss M, Kolb HC, Zhang JJ, et al. Biodistribution and radiation dosimetry of the integrin marker 18F-RGD-K5 determined from whole-body PET/CT in monkeys and humans. J Nucl Med 2012;53(5):787- 795.
34. Wan W, Guo N, Pan D, et al. First experience of 18F-alfatide in lung cancer patients using a new lyophilized kit for rapid radiofluorination. J Nucl Med 2013;54(5): 691-698.
35. Yang M, Gao H, Yan Y, et al. PET imaging of early response to the tyrosine kinase inhibitor ZD4190. Eur J Nucl Med Mol Imaging 2011;38(7):1237-1247.
36. Sun X, Yan Y, Liu S, et al. 18F-FPPRGD2 and 18F-FDG PET of response to Abraxane therapy. J Nucl Med 2011;52(1):140-146.